This project will investigate the short- and long-term multi-organ health of cancer patients and survivors in the UK Biobank, including cardiovascular, metabolic, musculoskeletal, mental well-being, and general physical health outcomes. Cancer groups will be defined using linked health data and characterised to include date of diagnosis, primary site, stage, and other key features (e.g. immunohistochemistry). Cancer treatment exposures (e.g., chemotherapy, radiotherapy, surgery, other systemic therapies) will be defined, creating a novel nomenclature designed for large-scale epidemiologic analysis. The work will leverage multimodal data types such as socio-demographic, lifestyle, blood biomarkers (standard haem/biochemistry, proteomics, metabolomics, genotyping), health record data including electronic health records (HES, GP), cancer treatment/registry (NCRAS, SACT), imaging (MRI, DEXA, ECG), and physical measures (wearables, blood pressure, lung function) to generate a comprehensive characterisation of multi-organ health and functional outcomes in this population and to advance risk prediction for adverse outcomes using a range of statistical and machine learning approaches.
